Oliver Luxxe Assets’s Catalyst Pharmaceutical CPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-49,744
Closed -$1.56M – 201
2026
Q2
$1.56M Sell
49,744
-46,892
-49% -$1.38M 0.23% 123
2026
Q1
$2.39M Buy
96,636
+19,589
+25% +$467K 0.36% 109
2025
Q4
$1.8M Buy
77,047
+1,646
+2% +$36.7K 0.27% 125
2025
Q3
$1.49M Buy
75,401
+4,161
+6% +$85.6K 0.24% 131
2025
Q2
$1.55M Buy
71,240
+935
+1% +$22.1K 0.28% 117
2025
Q1
$1.7M Buy
70,305
+36,280
+107% +$817K 0.32% 111
2024
Q4
$676K Hold
34,025
– – 0.12% 147
2024
Q3
$676K Buy
+34,025
New +$631K 0.12% 148

Other funds holding CPRX

Oliver Luxxe Assets's CPRX Position: Q3 2026 in Review

Oliver Luxxe Assets sold out of Catalyst Pharmaceutical (CPRX) in Q3 2026, closing a stake of 49,744 shares — an estimated $1.56M sold.

Oliver Luxxe Assets first reported a position in CPRX in Q3 2024 and held it in 8 quarters. The position peaked at $2.39M in Q1 2026. 2 funds tracked by Wall St. Rank hold CPRX as of Q3 2026.

  • Oliver Luxxe Assets reported no remaining Catalyst Pharmaceutical position as of Q3 2026 after selling out during the quarter.
  • Oliver Luxxe Assets sold 49,744 Catalyst Pharmaceutical shares in Q3 2026, an estimated $1.56M.
  • Oliver Luxxe Assets first reported a position in Catalyst Pharmaceutical in Q3 2024 and held it in 8 quarters.
  • Oliver Luxxe Assets's Catalyst Pharmaceutical position peaked at $2.39M in Q1 2026.
  • 2 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2026.

Based on Oliver Luxxe Assets's 13F filing for Q3 2026, filed 14 Oct 2026.